Axsome Therapeutics (NASDAQ:AXSM) Stock Price Target Cut by Royal Bank Of Canada

Posted by Francis Steltz on Oct 8th, 2026

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target cut by equities researchers at Royal Bank Of Canada from $297.00 to $295.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 74.39% from the stock’s previous close.

Several other equities analysts have also commented on AXSM. UBS Group reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Friday, July 17th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Truist Financial boosted their price objective on shares of Axsome Therapeutics from $200.00 to $285.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Finally, Piper Sandler reissued an “overweight” rating and set a $258.00 price objective on shares of Axsome Therapeutics in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $275.74.

Get Our Latest Report on Axsome Therapeutics

Axsome Therapeutics Stock Down 2.2%

Axsome Therapeutics stock traded down $3.81 during midday trading on Thursday, reaching $169.16. The company’s stock had a trading volume of 135,761 shares, compared to its average volume of 751,293. The stock’s 50-day simple moving average is $205.22 and its 200-day simple moving average is $212.78. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. Axsome Therapeutics has a 52-week low of $118.71 and a 52-week high of $260.19. The stock has a market capitalization of $8.86 billion, a P/E ratio of -45.37 and a beta of 0.86.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The business had revenue of $218.38 million during the quarter, compared to analyst estimates of $221.11 million. On average, sell-side analysts expect that Axsome Therapeutics will post -2.92 EPS for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the sale, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Herriot Tabuteau sold 4,660 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,546,644.55. This represents a 39.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 59,664 shares of company stock worth $12,624,805. 20.60% of the stock is owned by corporate insiders.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AXSM. BlackRock Inc. purchased a new position in Axsome Therapeutics during the second quarter valued at approximately $759,695,000. Assenagon Asset Management S.A. boosted its position in Axsome Therapeutics by 85.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 865,958 shares of the company’s stock worth $146,364,000 after purchasing an additional 397,976 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Axsome Therapeutics by 1,230.2% during the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock worth $97,606,000 after purchasing an additional 534,066 shares during the period. Bank of America Corp DE acquired a new stake in shares of Axsome Therapeutics during the 2nd quarter worth approximately $110,756,000. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Axsome Therapeutics during the 2nd quarter valued at approximately $55,171,000. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company uses differentiated product candidates and targeted mechanisms to address conditions with significant unmet medical needs, including depression, sleep disorders, migraine, and other neurological or psychiatric diseases.

Axsome’s lead commercial product is Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride), an oral medicine approved in the United States for the treatment of major depressive disorder in adults.